Provide details of the acquisition in cluding the date, par ties to and type of agreement (eg: sale, option, license etc.) and relationship to the Issuer. The disclosure should be sufficiently comple te to enable a reader to appreciate the significance of the acquisition without reference to any other material: Pursuant to a Letter Agreement dated March 22, 2014 and made between Supreme Pharmaceuticals Inc. and Ba ckroads Enterprises Ltd., as amended on April 5, 2014 and April 14, 2104, the Company acquired an option to purchase the facility for $125,000.00 in cash and $100,000.00 in common shares of the Company at a deemed pric e of $0.05 per share. The exercise price of the option is $1,250,000
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.